Systematic Inductive Method for Imputing Partial Missing Dates in Clinical Trials

Size: px
Start display at page:

Download "Systematic Inductive Method for Imputing Partial Missing Dates in Clinical Trials"

Transcription

1 Paper PO05 Systematic Inductive Method for Imputing Partial Missing Dates in Clinical Trials Ping Liu ABSTRACT In any phase of clinical trials, dates are very critical throughout the entire trial. However, since incomplete dates are inevitable during the clinical data collection process, and missing dates will cause numerous problems to the study, there is a need to investigate the method of handling the missing dates. We do have different imputation methods for partial missing dates in different companies or different therapeutic areas, but we don t have a systematic method for varied missing situations. Developing a systematic inductive method for imputing the missing dates in varied situations is the topic of this paper. The paper will categorize missing dates into three status (whole date missing, month and day missing, only day missing), and utilize a systematic inductive method to impute the partial missing dates. A simple SAS macro will be included. This method serves as a hint for handling missing dates in different situations and different time points. INTRODUCTION Working in different companies or different therapeutic areas, we often encounter the situation in which quite an amount of time is being spent to discuss rules and develop imputation algorithms when incomplete dates occur in different studies. Sometimes we don t even recognize that we have encountered and discussed the same situations before because these missing dates situations are handled on an ad-hoc basis rather than being summarized and processed in a systematic way. Thus, it doesn t matter whether the missing dates are the start date or end date of drug compliance, medication history, concomitant medication, AE; whether the missing dates are the study completion date, discontinued date or death date; whether the missing dates are the sample dates in LAB, ECG or Vital Signs. We can summarize the missing dates into three categories: (1) the whole date is missing, (2) both of day and month are missing and (3) only day is missing. Furthermore, the imputation algorithms are developed based on a target date. This paper will discuss all of the three missing categories, but mostly focus on categories (2) and (3). Section 1 will describe how to categorize the clinical trial missing dates and how to handle the whole missing dates. Section 2 will categorize the partial missing dates and define the target date and variables names to utilize a systematic inductive method for imputing partial missing dates. Section 3 will provide a SAS macro implementing the method described in Section 2.

2 1. WHOLE DATE MISSING In clinical trials, dates can be grouped according to their related procedures, date related to the medical intervention, date related to an unplanned event and date related to a planned clinical evaluation. No matter what type of date it is, complete date information should be collected whenever possible. However, due to numerous reasons, missing dates are very often seen in clinical trials at different stages. Missing dates may occur because of errors by patients, investigators or data monitors, or during the data transfer. No matter what the cause, missing dates can be categorized into (1) due to human error and (2) due to unknown reasons. Some human errors can be fixed by queries during the data cleaning process, but some human errors can not be fixed because of numerous reasons (e.g., tight timeline, clinical procedure orders, etc.). Those unfixed errors may cause problems in the analysis of the study. How to handle missing dates due to unfixed errors is the topic of this paper. Generally, the imputation algorithms depend on the type of events and the time when those missing dates occurred. Different cases may adopt different imputation algorithms, thus adopting appropriate imputations algorithm becomes critical. In some cases, the traditional last observation carried forward (LOCF) method can be adopted while in some other cases the imputation algorithm needs to be based on the specific situation. The imputation algorithms also need to be dependent on the way the data is collected. The following summarizes the type of date, according to the relationship to the clinical procedure, and some current practices of imputation when the whole date is missing. 1.1 Date of Intervention Date related to medical intervention such as investigational treatment, concurrent medical treatment or surgical procedures. In most cases, these dates are rarely missing, however, if the start date of the intervention is missing, an ad-hoc date is used to impute the missing date. If the end date of the intervention is missing, the date of the last visit to the clinical site is used to impute the missing date. If the interim date of intervention is missing, the corresponding interim visit date is used to impute the missing date. 1.2 Date of Events Date of occurrence or incidence which is independent of planned clinical evaluations. The examples of these dates are AE, Medical History or Concomitant Medications. It is common to see missing dates for these events, especially the month and day missing. The way to handle the missing whole date depends on the specific situation, where the LOCF is often used or the study cut point date is used to impute the missing end date. The interim study date (e.g. study visit date, lab date) sometimes is used to impute the missing interim date. 1.3 Date of Findings Date on which the results from planned evaluations are observed. The examples of these dates are physical exams, test results (ECG, LAB, Vital Signs, other tests), and questionnaires. It is rare that the planned evaluation date is missing. If it is missing, then it is common practice to use the closest visit date to impute the missing date.

3 2. PARTIAL DATE MISSING 2.1 Method and Definition In Section 1 we discussed the situations where the whole date (year, month and day) is missing. In this section, we will discuss the situations where only partial date (month or day) is missing. It is often seen in clinical trials that the date of some past event is often recalled by year or best by year and month. There are numerous methods available for handling the partial missing date. However, these methods are adopted on an ad-hoc basis and hence there is lack of consistency among these methods. A systematic way of handling the partial missing date is developed. The basic concept of this method is to impute the partial missing date based on a target date rather than using an ad-hoc date. The target date is defined as the reference date for the study analysis. It will be driving the points of the study analysis. We can define the treatment randomization date as the target date to impute the treatment start date. We can define the treatment start date as the target date to impute the AE partial missing dates. We can define the visit date as the target date to impute a partial missing date for planned evaluations dates etc. After target date is defined, we can sum up the imputation dates in three ways: 1. The imputing event date could only happen before the target date 2. The imputing event date could only happen after the target date 3. The imputing event date could happen either before or after the target date. We simplify all partial missing date imputations by the target date. How to distinguish it will be discuss in the following sections. 2.2 Define the Dates Variables Before we discuss the imputation methods, let us setup the date variables as follows: Variable name Datevar Yvar Mvar Dvar Trtstd Trty Trtm Trtd Variable descript event date event year event month event day target date target year target month target day 2.3 The Event Dates Occurred Before the Target Date For example of datasets: Randomization Datasets Medication History Concomitant History (sometimes) prior to start of study date Therapeutic Disease Medication prior to start of study date Any Medication Information prior to start of study date First study date is defined as the target date for those kinds of imputing partial missing date. For this type of partial missing date imputation proposal is as follows:

4 YVAR^=. YVAR^=TRTY MVAR=. 01/JULY/YVAR YVAR=TRTY MVAR=. MVAR^=TRTM MVAR=TRTM TRTSTD-1 15/MVAR/YVAR min(15/mvar/yvar,trtstd-1) 2.4 The Event Date Occurred After the Target Date For example of datasets: Adverse Events after treatment study date Study completion information after treatment study date For this type of dataset, partial missing date imputation proposal is as follows: YVAR^=. YVAR^=TRTY MVAR=. 01/JULY/YVAR YVAR=TRTY MVAR=. MVAR^=TRTM MVAR=TRTM TRTSTD+1 15/MVAR/YVAR max(15/mvar/yvar,trtstd+1) 2.5 The Event Date Occurred Crossing the Target Date For example of datasets: Vital signs A_VSN ECG Laboratory A_LRS Bone Markers Quality of Life YVAR^=. YVAR^=TRTY MVAR=. 01/JULY/YVAR YVAR=TRTY MVAR=. 01/JULY/YVAR 2.6 Summarized above three types of date sets imputation as follows: YVAR^=. YVAR^=TRTY MVAR=. 01/JULY/YVAR YVAR=TRTY MVAR=. 1. TRTSTD-1 if TRTSTD<01/JULY/YVAR 01/JULY/YVAR otherwise 2. TRTSTD+1 if TRTSTD>01/JULY/YVAR

5 01/JULY/YVAR otherwise 3. 01/JULY/YVAR MVAR^=. MVAR^=TRTM 15/MVAR/YVAR MVAR=TRTM 1.min(15/MVAR/YVAR,TRTSTD-1) 2.max(15/MVAR/YVAR,TRTSTD+1) 3. 15/MVAR/YVAR Notes: 1--The event dates in the dataset are happen before the target date. 2-- The event dates in the dataset are happen after the target date. 3-- The event dates in the dataset are happen crossing the target date In the summarized partial missing date imputation above, we can change imputation numbers of 01/JULY, 15, TRTSTD-1 and TRTSTD+1 to apply in terms of different purpose of the study analysis. 3. MACRO FOR IMPUTING PARTIAL MISSING DATES Based on the methods discussed in Section 2, a SAS macro is provided to implement these methods. The macro is simple, can be understood easily, and is also flexible. You may need to make a simple modification based on your target date to satisfy the macro s requirement. The program creating a dummy dataset is provided in Section 3.2. You will get tips for creating a dummy dataset and for how to manipulate dates. Two examples will show you how to handle and modify different date formats to apply the macro. 3.1 Macro for Partial Missing Dates ******************************************************** * Macro for impute partial missing dates * this macro can only be used inside data steps * all the parameter variables are assumed numeric except trtdt * macro variables definition: * datvar: imputed date * dvar: need to be imputed day * mvar: need to be imputed month * yvar: need to be imputed year * imflag: flag to be used for distinguishing type of imputing date * trtsdt: target variable * trty: year of the target date * trtm: month of the target date * trtd: day of the target date ***************************************************; %macro missdat(datvar=,dvar=, mvar=, yvar=,imflag=,trtsdt=, trty=,trtm=,trtd=); if &datvar eq. and &yvar ne. then do; if &mvar eq. then do; if &imflag=1 and &yvar=&trty and &trtsdt<input(( 01jul &yvar)d,date9.) then do; &mvar=&trtm; &dvar=&trtd.-1; end; else if &imflag=2 and &yvar=&trty and &trtsdt>input(( 01jul &yvar)d,date9.) then do; &mvar=&trtm; &dvar=&trtd.+1; end; else do; &mvar = 7; &dvar = 15; end;

6 end; else if &dvar eq. then do; if &imflag=1 and &trtd<&dvar and &yvar=&trty and &mvar=&trtm then &dvar=min(15,&trtd.-1); else if &imflag=2 and &trtd>&dvar and &yvar=&trty and &mvar=&trtm then &dvar=max(15,&trtd.+1); else &dvar = 15; end; datvar = mdy(&mvar,&dvar,&yvar); end; %mend missdat; 3.2 Dummy Datasets ************************************* * create a dummy datasets **************************************; data sample(keep=pat visit fdosdt mon day yr sdtc); retain pat visit fdosdt sampdtn sampdtc mon day yr sdtc; format fdosdt sampdtn date9.; do pat=1 to 5; fdosdt='15apr2003'd + pat*30; do visit=1 to 3; sampdtn='11apr2003'd+visit*2 +pat*30 ; sampdtc=put(sampdtn,date9.); if visit=2 and pat in(2,4) then do; yr=year(sampdtn); mon=.; day=.; end; else if visit=2 and pat in(3,5) then do; yr=year(sampdtn); mon=month(sampdtn); day=.; end; else if visit=3 and pat in(2,5) then do; yr=year(sampdtn); mon=.; day=.; end; else if visit=3 and pat in(1,2) then do; yr=year(sampdtn); mon=month(sampdtn); day=.;end; else do;yr=year(sampdtn);mon=month(sampdtn);day=day(sampdtn);end; if mon in(0,.) then do; sdtc=right(' ' put(yr,z4.)); end; else if day in(0,.) then do; sdtc=right(' ' substr(sampdtc,3,3) put(yr,z4.)); end; else sdtc=sampdtc; output; end; end; run; proc print; run; DATASET SAMPLE Obs pat visit fdosdt mon day yr sdtc MAY MAY MAY MAY MAY MAY JUN JUN JUN JUN

7 JUL JUL JUL JUL JUL JUL AUG AUG AUG AUG AUG SEP SEP SEP SEP SEP Examples ******************************************************************** Example 1. Each date already have separated year and month and day variables. *************************************************************************************; data sample1; set sample; trty=year(fdosdt); trtm=month(fdosdt); trtd=day(fdosdt); %missdat(datvar=impdt,dvar=day, mvar=mon, yvar=yr, imflag=1,trtsdt=fdosdt, trty=trty,trtm=trtm,trtd=trtd); run; ******************************************************************** Example 2. Sample date and target date do not have numerical year, month and day variables. *************************************************************************************; data sample2; set sample; format impdt date9.; **get year month and day variables from sample date; dday=input(substr(sdtc,1,2),best.); **month=letter for conversion; mon1 = '01' substr(sdtc,3,3) substr(sdtc,6); mon = month(input(mon1,?? date9.)); yr =input(substr(sdtc,6 ),best.); **get year month and day variables from target date; dayt=day(fdosdt); mont= month(fdosdt); yrt =year(fdosdt); %missdat(datvar=impdt2,dvar=dday, mvar=mon, yvar=yr,imflag=1,trtsdt=fdosdt,trty=yrt,trtm=mont,trtd=dayt); drop dday mon1 mon yr vis1d dayt mont yrt; run;

8 CONCLUSION Based on pharmaceutical industry experience, this presentation summarizes the simple ways to impute the whole missing date and develops a systematic method for imputing partial missing date. This presentation serves as a hint for the basic imputation references for missing dates as well as tips for using SAS date and string functions from the macro and samples, and tips for how to create a dummy dataset. ACKNOWLEDGEMENTS The author would like to thank Ms. Margaret McAlary, my supervisor, for her encouragement and comments during the development of this presentation. CONTACT INFORMATION Ping Liu Biostatistics & Statistical Reporting Novartis Pharmaceuticals Corporation One Health Plaza East Hanover, NJ ping.liu@novartis.com

A SAS sy Study of ediary Data

A SAS sy Study of ediary Data A SAS sy Study of ediary Data ABSTRACT PharmaSUG 2017 - Paper BB14 A SAS sy Study of ediary Data Amie Bissonett, inventiv Health Clinical, Minneapolis, MN Many sponsors are using electronic diaries (ediaries)

More information

Implementing Worst Rank Imputation Using SAS

Implementing Worst Rank Imputation Using SAS Paper SP12 Implementing Worst Rank Imputation Using SAS Qian Wang, Merck Sharp & Dohme (Europe), Inc., Brussels, Belgium Eric Qi, Merck & Company, Inc., Upper Gwynedd, PA ABSTRACT Classic designs of randomized

More information

What makes Oncology special? Johanna MURSIC, Indication Programmer PhUSE congress Budapest, October 15 th 2012

What makes Oncology special? Johanna MURSIC, Indication Programmer PhUSE congress Budapest, October 15 th 2012 What makes Oncology special? Johanna MURSIC, Indication Programmer PhUSE congress Budapest, October 15 th 2012 Disclaimer The opinions expressed in this presentation and on the following slides are solely

More information

PROGRAMMER S SAFETY KIT: Important Points to Remember While Programming or Validating Safety Tables

PROGRAMMER S SAFETY KIT: Important Points to Remember While Programming or Validating Safety Tables PharmaSUG 2012 - Paper IB09 PROGRAMMER S SAFETY KIT: Important Points to Remember While Programming or Validating Safety Tables Sneha Sarmukadam, Statistical Programmer, PharmaNet/i3, Pune, India Sandeep

More information

Paper number: CC02 MACRO %NEWFLOW JIAN HUA (DANIEL) HUANG, FOREST LABORATORIES INC, NJ

Paper number: CC02 MACRO %NEWFLOW JIAN HUA (DANIEL) HUANG, FOREST LABORATORIES INC, NJ Paper number: CC02 MACRO %NEWFLOW JIAN HUA (DANIEL) HUANG, FOREST LABORATORIES INC, NJ ABSTRACT: If you use SAS Proc Report frequently, you will be familiar with the flow option. The flow option wraps

More information

Pharmaceutical Applications

Pharmaceutical Applications Creating an Input Dataset to Produce Incidence and Exposure Adjusted Special Interest AE's Pushpa Saranadasa, Merck & Co., Inc. Abstract Most adverse event (AE) summary tables display the number of patients

More information

Immediate-release Hydrocodone/Acetaminophen M Abbreviated Clinical Study Report R&D/08/1020

Immediate-release Hydrocodone/Acetaminophen M Abbreviated Clinical Study Report R&D/08/1020 2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Hydrocodone Bitartrate- Acetaminophen (NORCO ) Name of

More information

Strategies for handling missing data in randomised trials

Strategies for handling missing data in randomised trials Strategies for handling missing data in randomised trials NIHR statistical meeting London, 13th February 2012 Ian White MRC Biostatistics Unit, Cambridge, UK Plan 1. Why do missing data matter? 2. Popular

More information

Individual Study Table Referring to Part of the Dossier. Volume:

Individual Study Table Referring to Part of the Dossier. Volume: 2 Synopsis Title of study: An Investigator-blind, Controlled Study to Assess the Efficacy of Five Distinct Combinations of in Different Concentrations Compared to Placebo and to Two Active Controls in

More information

A SAS Macro to Present a Summary Table of the Number of Patients Having Experienced Adverse Events in a Clinical Trial

A SAS Macro to Present a Summary Table of the Number of Patients Having Experienced Adverse Events in a Clinical Trial A SAS Macro to Present a Summary Table of the Number of Patients Having Experienced Adverse Events in a Clinical Trial Christoph Gerlinger * and Ursula Franke ** * Laboratoires Fournier S.C.A. and ** biodat

More information

Programmatic Challenges of Dose Tapering Using SAS

Programmatic Challenges of Dose Tapering Using SAS ABSTRACT: Paper 2036-2014 Programmatic Challenges of Dose Tapering Using SAS Iuliana Barbalau, Santen Inc., Emeryville, CA Chen Shi, Santen Inc., Emeryville, CA Yang Yang, Santen Inc., Emeryville, CA In

More information

Description and instructions for the use of SAS macros for the selfcontrolled

Description and instructions for the use of SAS macros for the selfcontrolled Description and instructions for the use of SAS macros for the selfcontrolled case series analyses Two SAS macros have been developed to analyse self-controlled case series (SCCS) data. The macro %SCCSDTA

More information

Collapsing Longitudinal Data Across Related Events and Imputing Endpoints

Collapsing Longitudinal Data Across Related Events and Imputing Endpoints Collapsing Longitudinal Data Across Related Events and Imputing Endpoints James Joseph, INC Research, King of Prussia, PA INTRODUCTION When attempting to answer a research question, the best study design

More information

BEST PRACTICES FOR IMPLEMENTATION AND ANALYSIS OF PAIN SCALE PATIENT REPORTED OUTCOMES IN CLINICAL TRIALS

BEST PRACTICES FOR IMPLEMENTATION AND ANALYSIS OF PAIN SCALE PATIENT REPORTED OUTCOMES IN CLINICAL TRIALS BEST PRACTICES FOR IMPLEMENTATION AND ANALYSIS OF PAIN SCALE PATIENT REPORTED OUTCOMES IN CLINICAL TRIALS Nan Shao, Ph.D. Director, Biostatistics Premier Research Group, Limited and Mark Jaros, Ph.D. Senior

More information

Improved Transparency in Key Operational Decisions in Real World Evidence

Improved Transparency in Key Operational Decisions in Real World Evidence PharmaSUG 2018 - Paper RW-06 Improved Transparency in Key Operational Decisions in Real World Evidence Rebecca Levin, Irene Cosmatos, Jamie Reifsnyder United BioSource Corp. ABSTRACT The joint International

More information

Insomnia: What Happens When You Can't Sleep By Donnee Patrese

Insomnia: What Happens When You Can't Sleep By Donnee Patrese Insomnia: What Happens When You Can't Sleep By Donnee Patrese If you are looking for a ebook Insomnia: What happens when you can't sleep by Donnee Patrese in pdf form, then you have come on to the right

More information

A SAS Application for Analyzing Quality of Life data: NCIC-CTG Standard Method

A SAS Application for Analyzing Quality of Life data: NCIC-CTG Standard Method Paper SP01 A SAS Application for Analyzing Quality of Life data: NCIC-CTG Standard Method Don (Dongguang) Li, NCIC-CTG, Queen s University, Kingston, ON, Canada ABSTRACT The Health-Related Quality of Life

More information

ABSTRACT INTRODUCTION

ABSTRACT INTRODUCTION Adaptive Randomization: Institutional Balancing Using SAS Macro Rita Tsang, Aptiv Solutions, Southborough, Massachusetts Katherine Kacena, Aptiv Solutions, Southborough, Massachusetts ABSTRACT Adaptive

More information

Methods for Computing Missing Item Response in Psychometric Scale Construction

Methods for Computing Missing Item Response in Psychometric Scale Construction American Journal of Biostatistics Original Research Paper Methods for Computing Missing Item Response in Psychometric Scale Construction Ohidul Islam Siddiqui Institute of Statistical Research and Training

More information

Maintenance of weight loss and behaviour. dietary intervention: 1 year follow up

Maintenance of weight loss and behaviour. dietary intervention: 1 year follow up Institute of Psychological Sciences FACULTY OF MEDICINE AND HEALTH Maintenance of weight loss and behaviour change Dropouts following and a 12 Missing week healthy Data eating dietary intervention: 1 year

More information

AE: An Essential Part of Safety Summary Table Creation. Rucha Landge, Inventiv International Pharma Services Pvt. Ltd.

AE: An Essential Part of Safety Summary Table Creation. Rucha Landge, Inventiv International Pharma Services Pvt. Ltd. PharmaSUG 2016 - Paper IB11 AE: An Essential Part of Safety Summary Table Creation. Rucha Landge, Inventiv International Pharma Services Pvt. Ltd., Pune, India ABSTRACT Adverse event (AE) summary tables

More information

Graph Display of Patient Profile Using SAS

Graph Display of Patient Profile Using SAS PharmaSUG 2018 - Paper DV-17 Graph Display of Patient Profile Using SAS Yanwei Han, Seqirus USA Inc., Cambridge, MA Hongyu Liu, Seqirus USA Inc., Cambridge, MA ABSTRACT We usually create patient profile

More information

Combining Electronic Diary Seizure Data with Visit-Based Seizure Data in the MONEAD Study

Combining Electronic Diary Seizure Data with Visit-Based Seizure Data in the MONEAD Study PharmaSUG 2018 - Paper RW-02 Combining Electronic Diary Seizure Data with Visit-Based Seizure Data in the MONEAD Study Julia Skinner and Ryan May, Emmes Corporation ABSTRACT Electronic diary (ediary) mobile

More information

Statistical Analysis Plan (SAP)

Statistical Analysis Plan (SAP) Statistical Analysis Plan (SAP) Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax in Ethiopia: a randomized controlled trial Contents

More information

Certificate Courses in Biostatistics

Certificate Courses in Biostatistics Certificate Courses in Biostatistics Term I : September December 2015 Term II : Term III : January March 2016 April June 2016 Course Code Module Unit Term BIOS5001 Introduction to Biostatistics 3 I BIOS5005

More information

How the ICH E9 addendum around estimands may impact our clinical trials

How the ICH E9 addendum around estimands may impact our clinical trials Danish Society for Biopharmaceutical Statistics Copenhagen October 26, 2017 How the ICH E9 addendum around estimands may impact our clinical trials Frank Bretz (Novartis) ICH E9(R1) Expert Working Group

More information

ADaM Tips for Exposure Summary

ADaM Tips for Exposure Summary ABSTRACT PharmaSUG China 2016 Paper 84 ADaM Tips for Exposure Summary Kriss Harris, SAS Specialists Limited, Hertfordshire, United Kingdom Have you ever created the Analysis Dataset for the Exposure Summary

More information

Note to the interviewer: Before starting the interview, ensure that a signed consent form is on file.

Note to the interviewer: Before starting the interview, ensure that a signed consent form is on file. STUDY QUESTIONNAIRE FOR PATIENT TELEPHONE SURVEY Note to the interviewer: Fill out prior to the interview: 1) Participant ID 2) Date of non-invasive treatment / / 3) Interviewer name 4) Date of interview

More information

A SAS Macro to Investigate Statistical Power in Meta-analysis Jin Liu, Fan Pan University of South Carolina Columbia

A SAS Macro to Investigate Statistical Power in Meta-analysis Jin Liu, Fan Pan University of South Carolina Columbia Paper 109 A SAS Macro to Investigate Statistical Power in Meta-analysis Jin Liu, Fan Pan University of South Carolina Columbia ABSTRACT Meta-analysis is a quantitative review method, which synthesizes

More information

Ms Masabata Annah Motaung, Agricultural Research Council-Onderstepoort Veterinary Institute

Ms Masabata Annah Motaung, Agricultural Research Council-Onderstepoort Veterinary Institute The value of adhering to turnaround times in the Bacteriology and Zoonotic Diseases Laboratories at Onderstepoort. An assessment over 2 years. Ms Masabata Annah Motaung, Agricultural Research Council-Onderstepoort

More information

An Introduction to Multiple Imputation for Missing Items in Complex Surveys

An Introduction to Multiple Imputation for Missing Items in Complex Surveys An Introduction to Multiple Imputation for Missing Items in Complex Surveys October 17, 2014 Joe Schafer Center for Statistical Research and Methodology (CSRM) United States Census Bureau Views expressed

More information

Statistical Analysis Plan FINAL. DexComG4 (DexCom Corporation) CGMMDI GOLD-Study

Statistical Analysis Plan FINAL. DexComG4 (DexCom Corporation) CGMMDI GOLD-Study 1.0 Page 1 of 15 FINAL DexComG4 (DexCom Corporation) CGMMDI GOLD-Study monitoring (CGM) in individuals with type 1 diabetes treated 2016-07-07 Approvals Name/Title: Nils-Gunnar Pehrsson / Statistiska Konsultgruppen,

More information

2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/573. (For National Authority Use Only) to Part of Dossier: Volume:

2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/573. (For National Authority Use Only) to Part of Dossier: Volume: 2.0 Synopsis Abbott Laboratories Name of Study Drug: Depakote ER Name of Active Ingredient: Divalproex sodium (ABT-711) Individual Study Table Referring to Part of Dossier: Volume: Page: (For National

More information

A journey towards estimand specification in pain: motivation and challenges

A journey towards estimand specification in pain: motivation and challenges Biostatistics Neuroscience Franchise A journey towards estimand specification in pain: motivation and challenges Francesca Callegari, PhD PSI Meeting Reading, UK Sep 27 th, 2017 pdated Slide Quote We shall

More information

Estimands. EFPIA webinar Rob Hemmings, Frank Bretz October 2017

Estimands. EFPIA webinar Rob Hemmings, Frank Bretz October 2017 Estimands EFPIA webinar Rob Hemmings, Frank Bretz October 2017 Why estimands? To explain which treatment effect is described to prescribers and other stakeholders. To align objectives with (design and)

More information

BRL /RSD-101C0F/1/CPMS-716. Report Synopsis

BRL /RSD-101C0F/1/CPMS-716. Report Synopsis Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-Term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive

More information

Stepwise method Modern Model Selection Methods Quantile-Quantile plot and tests for normality

Stepwise method Modern Model Selection Methods Quantile-Quantile plot and tests for normality Week 9 Hour 3 Stepwise method Modern Model Selection Methods Quantile-Quantile plot and tests for normality Stat 302 Notes. Week 9, Hour 3, Page 1 / 39 Stepwise Now that we've introduced interactions,

More information

Today s EPDs are not a middle point in evolution. They are one step down from the middle point in evolution. They share elements of desire and

Today s EPDs are not a middle point in evolution. They are one step down from the middle point in evolution. They share elements of desire and Today s EPDs are not a middle point in evolution. They are one step down from the middle point in evolution. They share elements of desire and fulfilment, but also of pure frustration. In line with tradition,

More information

A Practical Guide to Getting Started with Propensity Scores

A Practical Guide to Getting Started with Propensity Scores Paper 689-2017 A Practical Guide to Getting Started with Propensity Scores Thomas Gant, Keith Crowland Data & Information Management Enhancement (DIME) Kaiser Permanente ABSTRACT This paper gives tools

More information

NCC Pediatrics Continuity Clinic Curriculum: Medical Home Module 2 Well Visits

NCC Pediatrics Continuity Clinic Curriculum: Medical Home Module 2 Well Visits NCC Pediatrics Continuity Clinic Curriculum: Medical Home Module 2 Well Visits Overall Goal: To identify strategies for providing comprehensive care during a well visit. The provision of comprehensive

More information

Research Compliance and Quality Assurance Program (RCQA): Audit Checklist Subject Specific

Research Compliance and Quality Assurance Program (RCQA): Audit Checklist Subject Specific Protocol Title / Code: Sponsor: PI Name: Auditor Name: Audit Date(s): Subject #: Key Dates: Date participant was identified: Date of Initial Consent: Date of Optional Consent: Date of Re-consent(s): Date

More information

AUG Expert responses to issues raised by British Gas during the query period for the first draft 2017/18 AUG Statement, 14 March 2017.

AUG Expert responses to issues raised by British Gas during the query period for the first draft 2017/18 AUG Statement, 14 March 2017. AUG Expert responses to issues raised by British Gas during the query period for the first draft 2017/18 AUG Statement, 14 March 2017. Below are the issues raised by British Gas. Following each issue is

More information

****************************************************************************

**************************************************************************** ***************************************************************************** **Updated: 2014-AUGUST-15 **Project: Fully automated waist-worn accelerometer algorithm for children s sleep period time separate

More information

Me 9. Time. When It's. for a. By Robert Tannenboum./ Industrial'Relations

Me 9. Time. When It's. for a. By Robert Tannenboum./ Industrial'Relations W/ When It's for a Time CHANG Ei.. By Robert Tannenboum./ Me 9 j 1*j & I,, A reprint of the Institute of University oftcalifornia Los Angeles 24, California Industrial'Relations INST iutc OF INDUS ;Rl-L

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Tasigna) Reference Number: CP.PHAR.76 Effective Date: 09.01.11 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this

More information

What s New in SUDAAN 11

What s New in SUDAAN 11 What s New in SUDAAN 11 Angela Pitts 1, Michael Witt 1, Gayle Bieler 1 1 RTI International, 3040 Cornwallis Rd, RTP, NC 27709 Abstract SUDAAN 11 is due to be released in 2012. SUDAAN is a statistical software

More information

CONSENT FORM. The Full Study Title Should Be Placed Here. Principal Investigator: Dr. John Smith Sub-Investigator: Dr. Jane Smith

CONSENT FORM. The Full Study Title Should Be Placed Here. Principal Investigator: Dr. John Smith Sub-Investigator: Dr. Jane Smith CONSENT FORM The Full Study Title Should Be Placed Here. Principal Investigator: Dr. John Smith Sub-Investigator: Dr. Jane Smith Queen Elizabeth Hospital Queen Elizabeth Hospital 60 Riverside Drive 60

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Monitoring Protocol for Clozapine-induced Myocarditis. Copyright 2017, CAMH

Monitoring Protocol for Clozapine-induced Myocarditis. Copyright 2017, CAMH 1 Monitoring Protocol for Clozapine-induced Myocarditis 1 Agenda Problem Identification / Identification Importance / Importance Baseline Workflow Baseline Workflow Baseline Data Baseline Data Objectives

More information

Part I. Boolean modelling exercises

Part I. Boolean modelling exercises Part I. Boolean modelling exercises. Glucose repression of Icl in yeast In yeast Saccharomyces cerevisiae, expression of enzyme Icl (isocitrate lyase-, involved in the gluconeogenesis pathway) is important

More information

Statistical Analysis Plan RH01649 Version Document Identifier Effective Date eldo_clinical_doc Reason For Issue

Statistical Analysis Plan RH01649 Version Document Identifier Effective Date eldo_clinical_doc Reason For Issue STATISTICAL ANALYSIS PLAN FOR PROTOCOL RH01649 A Study to Assess Efficacy over Placebo and Speed of Onset of Pain Relief of New Panadol Extra as Compared to Ibuprofen in Episodic Tension Headache BIOSTATISTICS

More information

Online Supplement to A Data-Driven Model of an Appointment-Generated Arrival Process at an Outpatient Clinic

Online Supplement to A Data-Driven Model of an Appointment-Generated Arrival Process at an Outpatient Clinic Online Supplement to A Data-Driven Model of an Appointment-Generated Arrival Process at an Outpatient Clinic Song-Hee Kim, Ward Whitt and Won Chul Cha USC Marshall School of Business, Los Angeles, CA 989,

More information

INFORMATION BROCHURE - ALLOCATE

INFORMATION BROCHURE - ALLOCATE INFORMATION BROCHURE - ALLOCATE AustraLian Ovarian Cancer Assortment Trial Principal Investigator: Prof Michael Quinn, Royal Women s Hospital This Participant Information Sheet and Consent Form is 7 pages

More information

Designing and Analyzing RCTs. David L. Streiner, Ph.D.

Designing and Analyzing RCTs. David L. Streiner, Ph.D. Designing and Analyzing RCTs David L. Streiner, Ph.D. Emeritus Professor, Department of Psychiatry & Behavioural Neurosciences, McMaster University Emeritus Professor, Department of Clinical Epidemiology

More information

PROC SQL. By Becky Leung Alberta Health Services. Calgary SAS User Group Meeting Wednesday, October 08, 2014

PROC SQL. By Becky Leung Alberta Health Services. Calgary SAS User Group Meeting Wednesday, October 08, 2014 PROC SQL By Becky Leung Alberta Health Services Calgary SAS User Group Meeting Wednesday, October 08, 2014 WHAT IS PROC SQL? A Base SAS procedure that combines the functionality of DATA and PROC steps

More information

Single market, regulatory environment, industries under vertical legislation Pharmaceuticals : regulatory framework and market authorisations

Single market, regulatory environment, industries under vertical legislation Pharmaceuticals : regulatory framework and market authorisations EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals : regulatory framework and market authorisations Brussels,

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

Will your lungs regenerate after you quit smoking

Will your lungs regenerate after you quit smoking Will your lungs regenerate after you quit smoking The Borg System is 100 % Will your lungs regenerate after you quit smoking 30-3-2010 After quitting smoking, it is important to help the lungs. After quitting

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Lecture 2. Key Concepts in Clinical Research

Lecture 2. Key Concepts in Clinical Research Lecture 2 Key Concepts in Clinical Research Outline Key Statistical Concepts Bias and Variability Type I Error and Power Confounding and Interaction Statistical Difference vs Clinical Difference One-sided

More information

Efficacy/pharmacodynamics: 85 Safety: 89

Efficacy/pharmacodynamics: 85 Safety: 89 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: Sanofi Drug substance:

More information

Healthcare Research You

Healthcare Research You DL for Healthcare Goals Healthcare Research You What are high impact problems in healthcare that deep learning can solve? What does research in AI applications to medical imaging look like? How can you

More information

Draft ICH Guidance on Estimands and Sensitivity Analyses: Why and What?

Draft ICH Guidance on Estimands and Sensitivity Analyses: Why and What? Draft ICH Guidance on Estimands and Sensitivity Analyses: Why and What? Devan V. Mehrotra Merck Research Laboratories Acknowledgement: ICH E9/R1 Expert Working Group Conference on Statistical Issues in

More information

Extract Information from Large Database Using SAS Array, PROC FREQ, and SAS Macro

Extract Information from Large Database Using SAS Array, PROC FREQ, and SAS Macro SESUG 2016 Paper CC-160 Extract Information from Large Database Using SAS Array, PROC FREQ, and SAS Macro Lifang Zhang, Department of Biostatistics and Epidemiology, Augusta University ABSTRACT SAS software

More information

Has the UK had a double epidemic?

Has the UK had a double epidemic? Has the UK had a double epidemic? Dr Rodney P Jones Healthcare Analysis & Forecasting www.hcaf.biz hcaf_rod@yahoo.co.uk Introduction Outbreaks of a new type of epidemic, possibly due to immune manipulation,

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Thank you very much for your guidance on this revision. We look forward to hearing from you.

Thank you very much for your guidance on this revision. We look forward to hearing from you. 1 PAINTED BUNTING MANUSCRIPT REVIEW HISTORY REVISION NOTES FROM AUTHORS (ROUND 2) We would like to submit a revision of our manuscript. As you requested, we have run new studies that employ additional

More information

Clozapine Clinic Treatment Centre, St Georges Park

Clozapine Clinic Treatment Centre, St Georges Park Clozapine Clinic Treatment Centre, St Georges Park Patient Information Leaflet Shining a light on the future This leaflet is relevant to the following clinic: St Georges Park Hospital Morpeth Northumberland

More information

CP316 Microprocessor Sysytems and Interfacing Evaluation Results Wilfrid Laurier University

CP316 Microprocessor Sysytems and Interfacing Evaluation Results Wilfrid Laurier University CP316 Microprocessor Sysytems and Interfacing Terry Sturtevant This evaluation for the purpose of evaluating my teaching methods and your impressions of the course. It is anonymous and you can omit any

More information

Study Center(s): The study was conducted at 39 study sites in Japan.

Study Center(s): The study was conducted at 39 study sites in Japan. SYNOPSIS Issue Date: 20 NOVEMBER 2012 Name of Sponsor/Company Janssen Pharmaceutical K. K. Name of Finished Product CONCERTA Name of Active Ingredient(s) Methylphenidate HCl Protocol No.: JNS001-JPN-A01

More information

Cincinnati Children s Hospital Medical Center PHO/OVPCA Constipation Initiative Monthly Report February 2018

Cincinnati Children s Hospital Medical Center PHO/OVPCA Constipation Initiative Monthly Report February 2018 Cincinnati Children s Hospital Medical Center PHO/OVPCA Constipation Initiative Monthly Report February 2018 Aim: Project focus to embed evidence based protocol for the treatment of Constipation in the

More information

Paper DM05 Using Empirical Rules in Quality Control of Clinical Laboratory Data

Paper DM05 Using Empirical Rules in Quality Control of Clinical Laboratory Data Paper DM05 Using Empirical Rules in Quality Control of Clinical Laboratory Data ABSTRACT Faustino Daria, Jr. Senior Statistical Programmer Kendle International, Inc. Cincinnati, OH A statistical programmer

More information

Military Acute Concussion Evaluation

Military Acute Concussion Evaluation MACE Military Acute Concussion Evaluation Patient Name: Service Member ID#: Unit: Date of Injury: Time of Injury: Examiner: Date of Evaluation: Time of Evaluation: CONCUSSION SCREENING Complete this section

More information

Sociology 63993, Exam1 February 12, 2015 Richard Williams, University of Notre Dame,

Sociology 63993, Exam1 February 12, 2015 Richard Williams, University of Notre Dame, Sociology 63993, Exam1 February 12, 2015 Richard Williams, University of Notre Dame, http://www3.nd.edu/~rwilliam/ I. True-False. (20 points) Indicate whether the following statements are true or false.

More information

Clinical Trial Results Database Page 1

Clinical Trial Results Database Page 1 Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive

More information

Administrative Procedure

Administrative Procedure Durham Catholic District School Board The Board Title: Eyewash Stations and Safety Showers Procedure #: AP414-12 Administrative Area: Policy Reference: Human Resources and Administrative Services Emergency

More information

Imputing Dose Levels for Adverse Events

Imputing Dose Levels for Adverse Events Paper HO03 Imputing Dose Levels for Adverse Events John R Gerlach & Igor Kolodezh CSG Inc., Raleigh, NC USA ABSTRACT Besides the standard reporting of adverse events in clinical trials, there is a growing

More information

Version No. 7 Date: July Please send comments or suggestions on this glossary to

Version No. 7 Date: July Please send comments or suggestions on this glossary to Impact Evaluation Glossary Version No. 7 Date: July 2012 Please send comments or suggestions on this glossary to 3ie@3ieimpact.org. Recommended citation: 3ie (2012) 3ie impact evaluation glossary. International

More information

A COMPARISON OF IMPUTATION METHODS FOR MISSING DATA IN A MULTI-CENTER RANDOMIZED CLINICAL TRIAL: THE IMPACT STUDY

A COMPARISON OF IMPUTATION METHODS FOR MISSING DATA IN A MULTI-CENTER RANDOMIZED CLINICAL TRIAL: THE IMPACT STUDY A COMPARISON OF IMPUTATION METHODS FOR MISSING DATA IN A MULTI-CENTER RANDOMIZED CLINICAL TRIAL: THE IMPACT STUDY Lingqi Tang 1, Thomas R. Belin 2, and Juwon Song 2 1 Center for Health Services Research,

More information

Warfarin Help Documentation

Warfarin Help Documentation Warfarin Help Documentation Table Of Contents Warfarin Management... 1 iii Warfarin Management Warfarin Management The Warfarin Management module is a powerful tool for monitoring INR results and advising

More information

Chapter 11 Nonexperimental Quantitative Research Steps in Nonexperimental Research

Chapter 11 Nonexperimental Quantitative Research Steps in Nonexperimental Research Chapter 11 Nonexperimental Quantitative Research (Reminder: Don t forget to utilize the concept maps and study questions as you study this and the other chapters.) Nonexperimental research is needed because

More information

Measuring impact. William Parienté UC Louvain J PAL Europe. povertyactionlab.org

Measuring impact. William Parienté UC Louvain J PAL Europe. povertyactionlab.org Measuring impact William Parienté UC Louvain J PAL Europe povertyactionlab.org Course overview 1. What is evaluation? 2. Measuring impact 3. Why randomize? 4. How to randomize 5. Sampling and Sample Size

More information

2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/054. (For National Authority Use Only) Referring to Part of Dossier: Volume: Page:

2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/054. (For National Authority Use Only) Referring to Part of Dossier: Volume: Page: 2.0 Synopsis Abbott Laboratories Name of Study Drug: Depakote ER Name of Active Ingredient: Divalproex Sodium Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority

More information

Generate Informative Clinical Laboratory Results Listing

Generate Informative Clinical Laboratory Results Listing PharmaSUG2011 - Paper PO02 Generate Informative Clinical Laboratory Results Listing Sai Ma, Everest Clinical Research Services Inc., Markham, Ontario Canada ABSTRACT Clinical laboratory results review

More information

SAFETY AND EFFICACY ASSESSMENTS

SAFETY AND EFFICACY ASSESSMENTS SAFETY AND EFFICACY ASSESSMENTS The observations and procedures described in (Primary Arthritis Assessments) and the Hip or Knee Pain on motion assessment described in (Secondary Arthritis Assessment)

More information

Operator tooling for the Touch-up Procedure

Operator tooling for the Touch-up Procedure Operator tooling for the Touch-up Procedure Current State Current Process: After the printing process is complete part of the gold ink is not connected and the operator is required to touch-up this portion

More information

UN Handbook Ch. 7 'Managing sources of non-sampling error': recommendations on response rates

UN Handbook Ch. 7 'Managing sources of non-sampling error': recommendations on response rates JOINT EU/OECD WORKSHOP ON RECENT DEVELOPMENTS IN BUSINESS AND CONSUMER SURVEYS Methodological session II: Task Force & UN Handbook on conduct of surveys response rates, weighting and accuracy UN Handbook

More information

PFIZER INC. These results are supplied for informational purpose only. Prescribing decisions should be made based on the approved package insert.

PFIZER INC. These results are supplied for informational purpose only. Prescribing decisions should be made based on the approved package insert. Public Disclosure Synopsis Protocol A3924 4 November 24 Final PFIZER INC. These results are supplied for informational purpose only. Prescribing decisions should be made based on the approved package insert.

More information

INTRODUCTION TO MACHINE LEARNING. Decision tree learning

INTRODUCTION TO MACHINE LEARNING. Decision tree learning INTRODUCTION TO MACHINE LEARNING Decision tree learning Task of classification Automatically assign class to observations with features Observation: vector of features, with a class Automatically assign

More information

Kick It Old School - Creating Reports with the DATA _NULL_ Step

Kick It Old School - Creating Reports with the DATA _NULL_ Step Kick It Old School - Creating Reports with the DATA _NULL_ Step Sai Ma, PharmaNet/i3, Toronto, Ontario Canada Suwen Li, Everest Clinical Research Services Inc., Markham, Ontario Canada Minlan Li, Everest

More information

Sponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication

Sponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study

More information

Allergan Not Applicable AGN A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose, Parallel

Allergan Not Applicable AGN A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose, Parallel Peripheral Neuropathy Design, Dose Ranging Study of the Safety and Efficacy of AGN 203818 in Patients with Painful Diabetic 203818-004. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple

More information

Clinical Trial Report Synopsis

Clinical Trial Report Synopsis This document has been do\vnloaded from \v ww.leo-pharma.com subject to the terms of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment

More information

Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models, 2nd Ed.

Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models, 2nd Ed. Eric Vittinghoff, David V. Glidden, Stephen C. Shiboski, and Charles E. McCulloch Division of Biostatistics Department of Epidemiology and Biostatistics University of California, San Francisco Regression

More information

A (Constructive/Provocative) Critique of the ICH E9 Addendum

A (Constructive/Provocative) Critique of the ICH E9 Addendum A (Constructive/Provocative) Critique of the ICH E9 Addendum Daniel Scharfstein Johns Hopkins University dscharf@jhu.edu April 18, 2018 1 / 28 Disclosures Regularly consult with pharmaceutical and device

More information

Rapid Recovery Referral The Warm Handoff. Charles F. Barbera, MD, MBA, FACEP, FAAEM Chairman Department of Emergency Medicine

Rapid Recovery Referral The Warm Handoff. Charles F. Barbera, MD, MBA, FACEP, FAAEM Chairman Department of Emergency Medicine Rapid Recovery Referral The Warm Handoff Charles F. Barbera, MD, MBA, FACEP, FAAEM Chairman Department of Emergency Medicine Disclosures No relevant financial disclosures 2 Objectives Define rapid recovery

More information

Intro to SPSS. Using SPSS through WebFAS

Intro to SPSS. Using SPSS through WebFAS Intro to SPSS Using SPSS through WebFAS http://www.yorku.ca/computing/students/labs/webfas/ Try it early (make sure it works from your computer) If you need help contact UIT Client Services Voice: 416-736-5800

More information

Modeling of Hippocampal Behavior

Modeling of Hippocampal Behavior Modeling of Hippocampal Behavior Diana Ponce-Morado, Venmathi Gunasekaran and Varsha Vijayan Abstract The hippocampus is identified as an important structure in the cerebral cortex of mammals for forming

More information

ZITHROMAX (AZITHROMYCIN) SNDA H.3 CLINICAL TRIALS RELEVANT TO THE CLAIM STRUCTURE TABLE OF CONTENTS H.3.A. GENERAL APPROACH TO EVALUATION...

ZITHROMAX (AZITHROMYCIN) SNDA H.3 CLINICAL TRIALS RELEVANT TO THE CLAIM STRUCTURE TABLE OF CONTENTS H.3.A. GENERAL APPROACH TO EVALUATION... ZITHROMAX (AZITHROMYCIN) SNDA H.3 CLINICAL TRIALS RELEVANT TO THE CLAIM STRUCTURE TABLE OF CONTENTS H.3.A. GENERAL APPROACH TO EVALUATION...2 H.3.A.1 Efficacy (Pfizer IND Studies)...2 H.3.A.1.A Summary

More information